List of Excipients in Branded Drug XOLEGEL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Almirall LLC	XOLEGEL	ketoconazole	16110-080	ALCOHOL
Almirall LLC	XOLEGEL	ketoconazole	16110-080	ASCORBIC ACID
Almirall LLC	XOLEGEL	ketoconazole	16110-080	BUTYLATED HYDROXYTOLUENE
Almirall LLC	XOLEGEL	ketoconazole	16110-080	CITRIC ACID MONOHYDRATE
Almirall LLC	XOLEGEL	ketoconazole	16110-080	D&C YELLOW NO. 10

Xolegel Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Xolegel is a prescription topical gel containing ketoconazole 2% for seborrheic dermatitis in patients aged 12 years and older. Its excipient system is technically conventional and largely off-patent: carbomer, propylene glycol, isopropyl myristate, polysorbate 20, edetate disodium, sodium hydroxide, and purified water. The main commercial opportunity is therefore not ownership of the existing excipients. It is development of a bioequivalent generic, a more cosmetically acceptable formulation, or a differentiated ketoconazole delivery system with improved tolerability, packaging, or adherence.

What is Xolegel and what is its FDA regulatory status?

Xolegel is ketoconazole 2% gel, marketed for topical treatment of seborrheic dermatitis. The product is applied once daily for two weeks. The FDA-approved product is associated with NDA 021844 and was approved in 2006.[1]

Attribute	Xolegel profile
Active ingredient	Ketoconazole
Strength	2% w/w
Dosage form	Topical gel
Route	Cutaneous
Primary indication	Seborrheic dermatitis
Patient population	Adults and pediatric patients 12 years and older
Dosing	Once daily for two weeks
Regulatory pathway	New drug application
FDA approval	2006
Product type	Prescription topical dermatological drug

Ketoconazole is an imidazole antifungal that inhibits fungal ergosterol synthesis. In seborrheic dermatitis, the commercial value of the product depends on local delivery, low irritation, rapid spreading and acceptable cosmetic feel rather than systemic exposure.

The product’s formulation creates a relatively low technical barrier to entry compared with emulsions, liposomes, nanosuspensions or complex transdermal systems. A competitor can potentially use the same active ingredient and a similar excipient architecture, provided it satisfies applicable FDA quality, sameness and bioequivalence requirements.

What excipients are used in Xolegel?

The Xolegel label identifies the following inactive ingredients:

Excipient	Functional role in the formulation	Commercial relevance
Carbomer 934P	Gelling and viscosity-control polymer	Controls spreadability, residence time and rheology
Propylene glycol	Cosolvent and humectant	Supports wetting, solubilization and skin feel
Isopropyl myristate	Emollient and penetration-supporting vehicle	Improves spreadability and sensory profile
Polysorbate 20	Surfactant and solubilizer	Supports uniform ketoconazole distribution
Edetate disodium	Chelating agent	Binds trace metals and can support stability
Sodium hydroxide	pH adjuster and carbomer neutralizer	Develops gel structure and sets final pH
Purified water	Primary vehicle	Continuous phase of the gel

The excipient system has three formulation objectives. First, it must maintain ketoconazole in a physically stable state. Second, it must create a gel that remains on the scalp and affected skin long enough to support local treatment. Third, it must avoid excessive irritation, greasiness or residue that could reduce adherence.

The formulation is not protected commercially by the mere use of these common excipients. Any enforceable protection would more likely depend on a specific composition, concentration range, manufacturing process, particle-size distribution, rheological profile, packaging configuration or clinical performance claim.

How does the Xolegel excipient system work?

Carbomer and sodium hydroxide

Carbomer provides the gel network. Sodium hydroxide neutralizes the polymer and increases viscosity. The final pH is commercially important because it affects:

• Carbomer swelling and gel strength
• Ketoconazole chemical stability
• Skin tolerability
• Preservative performance, if a preservative system is used
• Product uniformity during filling and dispensing

Small changes in neutralization can materially change yield stress, viscosity and extrudability. A generic manufacturer that matches only nominal ingredients but produces a different rheological profile may face greater bioequivalence and performance risk.

Propylene glycol

Propylene glycol can act as a cosolvent and humectant. It can improve wetting of the stratum corneum and help maintain a workable gel during application. It can also contribute to stinging or irritation in susceptible patients. A lower-propylene-glycol formulation could have commercial value if it maintains ketoconazole delivery while improving tolerability.

Isopropyl myristate

Isopropyl myristate is an emollient ester that improves slip and skin feel. It can also influence drug partitioning into the skin and the final sensory profile. Its concentration affects greasiness, residue and spreadability. Replacing it with a different ester may create a more cosmetically attractive product, but the replacement can alter drug release and local bioavailability.

Polysorbate 20

Polysorbate 20 assists dispersion and solubilization. It can also affect micellar behavior and the thermodynamic activity of ketoconazole. Excess surfactant may increase irritation or destabilize the formulation. A competitor should evaluate surfactant level against particle growth, drug release, viscosity and skin tolerability rather than treating it as a simple inactive ingredient.

Edetate disodium

Edetate disodium is a low-cost chelator. It can reduce metal-catalyzed degradation and improve formulation robustness. Its value is mainly technical. It is unlikely to support a standalone commercial differentiation strategy.

What formulation patents protect Xolegel?

The commercial freedom-to-operate question depends on current U.S. patent records, Orange Book entries, continuation patents and litigation history. Xolegel’s active ingredient, ketoconazole, is an established compound, and its listed excipients are widely used pharmaceutical materials. Basic use of ketoconazole 2% in a topical gel is therefore unlikely to create a durable exclusivity position by itself.

The relevant patent categories are:

1. Composition patents. These may claim particular ratios of carbomer, propylene glycol, surfactant, emollient and ketoconazole.
2. Vehicle patents. These may claim a specific aqueous gel, hydroalcoholic system, emulsion or solubilized formulation.
3. Manufacturing patents. These may cover order of addition, neutralization, homogenization, deaeration or control of ketoconazole particle size.
4. Method-of-use patents. These may claim dosing schedules, treatment of a defined patient subgroup or treatment of a specific dermatological condition.
5. Packaging patents. These may cover tubes, pumps, metered dispensers or systems designed to reduce contamination and improve dosing.

The original Xolegel exclusivity period has expired. Any current barrier must therefore arise from a later patent, regulatory exclusivity, product-specific litigation or technical complexity. FDA approval does not establish that all patent rights have expired, and Orange Book patent data must be assessed separately from the product label.[2]

No biosimilar pathway applies. Xolegel is a small-molecule topical drug, so competitive products would generally proceed through an abbreviated new drug application or a full NDA, not a biosimilar application.

When does Xolegel lose exclusivity?

Xolegel’s statutory new chemical entity exclusivity would have expired years ago because the product was approved in 2006. The relevant commercial issue is generic entry, not loss of first-cycle regulatory exclusivity.

For a topical ketoconazole gel, generic entry can occur through:

• An ANDA demonstrating pharmaceutical equivalence and bioequivalence
• A 505(b)(2) application using literature, reference-product data or a modified formulation
• A full NDA for a materially differentiated product

A Paragraph IV certification could challenge any unexpired Orange Book-listed patent. If no blocking patent remains, an ANDA applicant may certify that the relevant patent has expired or is not listed. A Paragraph IV filing can trigger patent litigation and, if litigation is filed within the statutory period, a temporary FDA approval stay.[3]

Likely generic launch scenarios

Scenario	Commercial effect
No unexpired blocking patent	Earliest approval depends on ANDA review, manufacturing readiness and market economics
Paragraph IV challenge with litigation	Launch timing depends on court outcome, settlement terms or patent expiration
Authorized generic	Can reduce price while preserving manufacturer control
Several ANDA entrants	Rapid price erosion and pharmacy substitution
One or two technically differentiated entrants	More stable pricing, particularly if product feel or packaging is superior
Reformulated 505(b)(2) product	Potentially higher margin, but requires clinical and regulatory investment

What is the commercial opportunity for a Xolegel generic?

The most direct opportunity is a low-cost generic that matches the reference product’s critical quality attributes. The product has a simple dosage form, an established active ingredient and a familiar topical indication. Those factors support relatively low development cost compared with complex dermatology products.

The principal technical risks are:

• Ketoconazole crystallization or precipitation
• Inconsistent gel viscosity
• Drug-content nonuniformity
• Poor tube or pump compatibility
• Phase separation
• Variable in vitro release
• Skin irritation caused by solvent or surfactant levels
• Failure to match the reference product’s microstructure

A generic developer should prioritize equivalence in the following sequence:

1. Ketoconazole assay and content uniformity
2. pH and viscosity
3. Particle-size distribution or drug physical state
4. In vitro release rate
5. Water activity and microbial quality
6. Package compatibility
7. Comparative skin permeation or dermatopharmacokinetic performance, where required
8. Sensory attributes, including spreadability and residue

For a topical gel, simple Q1 sameness, meaning the same inactive ingredients, may not be enough to ensure practical equivalence. Q2 sameness, meaning the same concentrations, and Q3 equivalence, meaning comparable microstructure and physical properties, can reduce regulatory and commercial risk.

What excipient changes could create commercial differentiation?

Lower-irritation formulation

A formulation with reduced propylene glycol or a different surfactant system could target patients who experience burning or stinging. This strategy requires proof that ketoconazole remains adequately solubilized or dispersed and that local drug delivery is not reduced.

Improved cosmetic profile

A less tacky, faster-drying gel could compete on adherence. Relevant levers include:

• Alternative carbomer grades
• Lower residual solvent perception
• Modified emollient selection
• Reduced residue after drying
• Improved washability
• Non-greasy finish

Cosmetic differentiation may be more commercially important than a small change in antifungal activity because seborrheic dermatitis is often treated repeatedly and patients may discontinue unpleasant products.

Pump or metered packaging

A pump can reduce contamination and improve dose consistency. It may also support premium positioning. Packaging must be evaluated for adsorption, extractables, leachables, priming behavior and compatibility with the gel’s viscosity.

Preservative-minimized or preservative-free presentation

The listed Xolegel formulation does not rely on a conventional antimicrobial preservative in the inactive-ingredient list. This may provide a positioning advantage for sensitive-skin users. A competing formulation should preserve microbiological quality without adding a preservative that increases irritation or changes the regulatory profile.

Alternative delivery systems

Potential 505(b)(2) opportunities include:

• Hydroalcoholic gels
• Emulgels
• Foams
• Lipid-based gels
• Film-forming gels
• Sprayable or pump-dispensed systems
• Micellar or nanoparticle formulations

These systems can create stronger intellectual-property positions, but they also increase development cost and the risk of requiring clinical evidence beyond a conventional ANDA.

How does Xolegel compare with competing ketoconazole products?

Product type	Active ingredient	Formulation	Competitive position
Xolegel	Ketoconazole 2%	Gel	Prescription, localized treatment, cosmetic-feel differentiation
Ketoconazole cream	Ketoconazole 2%	Cream	Broader topical familiarity, potentially more emollient
Ketoconazole shampoo	Ketoconazole 2%	Shampoo	Scalp-focused, wash-off administration
Ketoconazole foam	Ketoconazole 2%	Foam	Higher convenience and cosmetic appeal, more complex delivery
Ciclopirox products	Ciclopirox	Cream, gel, shampoo or suspension depending on product	Alternative antifungal mechanism and competitive prescribing
Topical corticosteroid combinations	Corticosteroid plus antifungal or other agent	Cream, lotion or solution	May provide faster anti-inflammatory relief but has steroid-related limitations

Xolegel competes most directly with ketoconazole cream and shampoo. Its commercial advantage is the leave-on gel format. Its disadvantage is that a gel can be less familiar or less cosmetically acceptable than a shampoo for scalp disease and less emollient than a cream for dry lesions.

Which companies are challenging Xolegel?

The relevant challenger group consists of generic dermatology manufacturers and contract development organizations with topical semisolid capabilities. The commercial threat is determined less by the number of potential manufacturers than by:

• Access to pharmaceutical-grade ketoconazole
• Carbomer and surfactant sourcing
• Demonstrated topical bioequivalence capability
• Tube or pump filling capacity
• FDA inspection history
• Ability to support low-margin generic economics
• Willingness to litigate a Paragraph IV case

The product is vulnerable to price competition if multiple ANDA-approved versions reach the market. A manufacturer with a differentiated delivery system could avoid direct price competition but would face higher regulatory and clinical costs.

What licensing and partnership opportunities exist?

Licensing opportunities are strongest in three areas:

1. Generic commercialization. A formulation developer can license a ready-to-file or approved ANDA to a dermatology-focused commercial partner.
2. Excipient or delivery technology. A proprietary emulgel, film-forming polymer, pump system or irritation-reduction platform can be applied to ketoconazole and other topical drugs.
3. Geographic expansion. Regional partners can commercialize ketoconazole gel in markets where seborrheic dermatitis treatment remains fragmented and topical generics are less consolidated.

The most defensible licensing package would combine formulation know-how, comparative release data, validated manufacturing controls and regulatory documentation. A simple list of commonly available excipients has limited licensing value.

What patent and manufacturing barriers remain?

Manufacturing barriers are moderate, not high. The active pharmaceutical ingredient is established, and the excipients are commercially available. The more important barriers are process consistency and product performance.

Critical process parameters include:

• Carbomer hydration time
• Order of excipient addition
• Neutralization rate
• Mixing shear
• Temperature control
• Deaeration
• Ketoconazole dispersion
• Filling viscosity
• Bulk-hold time

A patentable manufacturing process would need to claim a non-obvious relationship between process conditions and a measurable product attribute, such as reduced crystallization, improved release uniformity or enhanced stability.

Geographic protection is also limited by the fact that excipients are broadly commoditized. Stronger country-level protection would require jurisdiction-specific formulation or process patents, trademarks, regulatory exclusivity or manufacturing know-how.

What is the revenue exposure and market outlook?

Revenue exposure depends on whether the product is marketed as a branded prescription drug, an authorized generic or a conventional generic. The product’s principal risk is rapid substitution after generic entry. A reformulated product with superior sensory performance could preserve pricing, but the indication is mature and competing therapies are readily available.

The highest-value commercial attributes are:

• Once-daily dosing
• Low irritation
• Fast drying
• Low residue
• Easy scalp application
• Stable product without refrigeration
• Reliable pump or tube delivery
• Broad pharmacy distribution

The lowest-value attributes are minor changes to chelators, water content or polymer grade that do not improve clinical, sensory or manufacturing performance.

Key Takeaways

• Xolegel is ketoconazole 2% topical gel for seborrheic dermatitis.
• Its listed excipients are carbomer 934P, propylene glycol, isopropyl myristate, polysorbate 20, edetate disodium, sodium hydroxide and purified water.
• The core excipient system is conventional and unlikely to create a strong standalone exclusivity position.
• The strongest near-term opportunity is a bioequivalent generic with tightly controlled rheology, drug distribution, release and packaging compatibility.
• Premium opportunities require improved cosmetic feel, lower irritation, better dispensing or a differentiated delivery system.
• Xolegel has no biosimilar pathway because ketoconazole is a small-molecule active ingredient.
• Any current Paragraph IV risk depends on live Orange Book patent records and unexpired formulation or method-of-use claims.
• Manufacturing know-how may be more valuable than the individual excipients.
• A simple excipient substitution has limited commercial value unless it produces measurable advantages in tolerability, adherence, stability or drug delivery.

FAQs

Is Xolegel the same as ketoconazole cream?

No. Both may contain ketoconazole 2%, but Xolegel is a leave-on gel with a different vehicle, rheology and sensory profile.

Can propylene glycol be removed from a Xolegel generic?

It can be considered, but removal may change ketoconazole solubilization, viscosity, release and skin delivery. The resulting product may require a different regulatory pathway.

Is Xolegel suitable for an OTC switch?

An OTC switch would require FDA review of safety, labeling, consumer usability and the appropriateness of nonprescription self-diagnosis. Prescription-to-OTC status cannot be inferred from the formulation alone.

What is the most valuable Xolegel formulation improvement?

A product that dries faster, leaves less residue and causes less irritation while preserving ketoconazole delivery would have the clearest commercial differentiation.

Can a new Xolegel formulation receive patent protection?

Potentially. Protection would depend on novel and non-obvious composition ranges, microstructure, manufacturing controls, delivery performance or treatment methods, not on the routine use of individual excipients.

References

1. U.S. Food and Drug Administration. (2006). Xolegel (ketoconazole) gel, 2% prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2017). Approved drug products and therapeutic equivalence evaluations: Patent and exclusivity information.
4. National Library of Medicine. (2024). DailyMed: Xolegel ketoconazole gel, 2%.
5. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Aqueous and non-aqueous topical semisolid dosage forms: Product quality tests.